An analysis of risk factors for developing hepatocellular carcinoma in a group of hepatitis C patients with stage 3 fibrosis following interferon therapy

Sabina Mahmood, Kazumi Togawa, Miwa Kawanaka, Gouichi Niiyama, Gotaro Yamada

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The risk of Hepatocellular carcinoma (HCC) is high in HCV-infected patients who have biochemically and histologically active chronic hepatitis. To observe the long prognosis of Chronic Hepatitis C (CHC) patients with stage 3 fibrosis (F3), 55 CHC patients after initial Interferon (IFN) therapy were followed up for up to 12 years (average 9.8 ± 2.3 years). According to the annual average alanine aminotransferase (ALT) levels, patients were grouped into, low (ALT ≦ 30 IU/l); moderate (ALT >30

Original languageEnglish
Pages (from-to)381-387
Number of pages7
JournalCancer Informatics
Volume6
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

Hepatitis C
Interferons
Hepatocellular Carcinoma
Fibrosis
Alanine Transaminase
Chronic Hepatitis C
Chronic Hepatitis
Therapeutics

Keywords

  • Alanine aminotransferase
  • Anti-inflammatory drugs
  • Chronic hepatitis C
  • Hepatocellular carcinoma
  • Long prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

An analysis of risk factors for developing hepatocellular carcinoma in a group of hepatitis C patients with stage 3 fibrosis following interferon therapy. / Mahmood, Sabina; Togawa, Kazumi; Kawanaka, Miwa; Niiyama, Gouichi; Yamada, Gotaro.

In: Cancer Informatics, Vol. 6, 2008, p. 381-387.

Research output: Contribution to journalArticle

@article{5154137c93ff4163bc20bf5b2824bebd,
title = "An analysis of risk factors for developing hepatocellular carcinoma in a group of hepatitis C patients with stage 3 fibrosis following interferon therapy",
abstract = "The risk of Hepatocellular carcinoma (HCC) is high in HCV-infected patients who have biochemically and histologically active chronic hepatitis. To observe the long prognosis of Chronic Hepatitis C (CHC) patients with stage 3 fibrosis (F3), 55 CHC patients after initial Interferon (IFN) therapy were followed up for up to 12 years (average 9.8 ± 2.3 years). According to the annual average alanine aminotransferase (ALT) levels, patients were grouped into, low (ALT ≦ 30 IU/l); moderate (ALT >30",
keywords = "Alanine aminotransferase, Anti-inflammatory drugs, Chronic hepatitis C, Hepatocellular carcinoma, Long prognosis",
author = "Sabina Mahmood and Kazumi Togawa and Miwa Kawanaka and Gouichi Niiyama and Gotaro Yamada",
year = "2008",
language = "English",
volume = "6",
pages = "381--387",
journal = "Cancer Informatics",
issn = "1176-9351",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - An analysis of risk factors for developing hepatocellular carcinoma in a group of hepatitis C patients with stage 3 fibrosis following interferon therapy

AU - Mahmood, Sabina

AU - Togawa, Kazumi

AU - Kawanaka, Miwa

AU - Niiyama, Gouichi

AU - Yamada, Gotaro

PY - 2008

Y1 - 2008

N2 - The risk of Hepatocellular carcinoma (HCC) is high in HCV-infected patients who have biochemically and histologically active chronic hepatitis. To observe the long prognosis of Chronic Hepatitis C (CHC) patients with stage 3 fibrosis (F3), 55 CHC patients after initial Interferon (IFN) therapy were followed up for up to 12 years (average 9.8 ± 2.3 years). According to the annual average alanine aminotransferase (ALT) levels, patients were grouped into, low (ALT ≦ 30 IU/l); moderate (ALT >30

AB - The risk of Hepatocellular carcinoma (HCC) is high in HCV-infected patients who have biochemically and histologically active chronic hepatitis. To observe the long prognosis of Chronic Hepatitis C (CHC) patients with stage 3 fibrosis (F3), 55 CHC patients after initial Interferon (IFN) therapy were followed up for up to 12 years (average 9.8 ± 2.3 years). According to the annual average alanine aminotransferase (ALT) levels, patients were grouped into, low (ALT ≦ 30 IU/l); moderate (ALT >30

KW - Alanine aminotransferase

KW - Anti-inflammatory drugs

KW - Chronic hepatitis C

KW - Hepatocellular carcinoma

KW - Long prognosis

UR - http://www.scopus.com/inward/record.url?scp=49649090335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49649090335&partnerID=8YFLogxK

M3 - Article

C2 - 19259418

AN - SCOPUS:49649090335

VL - 6

SP - 381

EP - 387

JO - Cancer Informatics

JF - Cancer Informatics

SN - 1176-9351

ER -